Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 ...
Ophthalmology Times

Sandoz Canada launches aflibercept biosimilar, Enzeevum

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus ...